Quantifying the benefit of non-small-cell lung cancer immunotherapy
Ethan B Ludmir1, Zachary R McCaw2, Aaron J Grossberg3
1University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lancet (London, England)
|November 29, 2019
Abstract
No abstract available in PubMed .
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.6K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.8K
